Article

Apoptosis in spermatocytic and usual seminomas: a light microscopic and immunohistochemical study.

Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Modern Pathology (Impact Factor: 6.36). 11/2007; 20(10):1036-44. DOI: 10.1038/modpathol.3800933
Source: PubMed

ABSTRACT Despite its alarming appearance, spermatocytic seminoma virtually never metastasizes. We hypothesized that this paradox may at least be partially related to increased apoptosis compared to metastasizing germ cell tumors since high expression of proapoptotic factors correlates with indolent behavior in other tumor systems, notably CD30-positive cutaneous lymphoma, another neoplasm where phenotype and behavior do not match. We therefore compared apoptosis and apoptotic regulators in 17 spermatocytic seminomas (2 with sarcoma) and 18 usual seminomas by light microscopy and using immunostains for caspase-3, p53, bcl-2, bcl-xL, FADD, FAS and survivin. We found significantly greater numbers of apoptotic cells and activated caspase-3-positive cells in spermatocytic seminoma compared to usual seminoma (P<0.01). There was over a 10-fold range in apoptotic cells in usual seminoma but only a 4-fold variation in spermatocytic seminoma. Spermatocytic seminoma had decreased p53 expression compared to usual seminoma, with marked variation in bcl-2 expression and increased FADD. The two sarcomas in spermatocytic seminoma, however, showed decreased apoptosis and caspase-3 reactivity, with upregulation of p53 and bcl-2 and decreased FADD expression. We conclude that apoptosis, caspase-3 and FADD expression are increased in spermatocytic seminoma compared to usual seminoma. Apoptotic parameters are decreased in sarcomatous transformation of spermatocytic seminoma. The increased apoptosis of spermatocytic seminoma, possibly mediated by FAS independent activation of the death receptor pathway, may provide some insight into its excellent prognosis. The variation in apoptosis of usual seminomas merits investigation as a prognostic parameter.

Download full-text

Full-text

Available from: Sunil Badve, Mar 06, 2015
0 Followers
 · 
76 Views
 · 
22 Downloads
  • Source
    • "The glass cover of crawling cell was prepared. The cover glass nearly full of cell on its surface was taken for H&E staining, with procedure according to reference [24]–[25]. The method used to observe the apoptosis of SKOV3 cells with transmission electron microscope has been described previously [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bioactive peptides, either derived from nature resources or synthesized by rational design, have been demonstrated potential for therapeutic agents against numerous human diseases, including cancer. However, the mechanism of therapeutic peptides against cancer has not been well elucidated. Here we show that PGPIPN, a hexapeptide derived from bovine β-casein, inhibited the proliferation of human ovarian cancer cells line SKOV3 as well as the primary ovarian cancer cells in vitro. Consistently, PGPIPIN also decreased tumor growth rate in xenograft ovarian cancer model mice in a dose-dependent manner. Further study demonstrated that the anti-tumor effect of PGPIPN is partially through promoting cell apoptosis by inhibiting BCL2 pathway. Thus, our study suggests that PGPIPN is a potential therapeutic agent for the treatment of ovarian cancer or other types of cancer.
    PLoS ONE 04/2013; 8(4):e60701. DOI:10.1371/journal.pone.0060701 · 3.23 Impact Factor
    • "This is in contrast with other epithelial tumors in which association with tumor grade is inverse, as in oral squamous cell carcinoma.[16] Similarly, apoptotic count is increased in non-small cell carcinoma of lung[17] and also in spermatocytic seminoma[18] (compared to the usual seminoma) that may provide some insight into the excellent prognosis of these tumors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many studies have been done in the past on the correlation between apoptotic count and histological grading of different tumors. The study aims to find out if a correlation between apoptotic count and histological grading exists in squamous cell carcinoma of the esophagus, and also to review the literature on such a relationship in the context of some other tumors. Cases of squamous cell carcinoma of the esophagus who presented at a tertiary care center over a period of one year were reviewed. The endoscopic biopsy specimens of 56 patients of squamous cell carcinoma of esophagus were fixed in 10% buffered formalin, processed for routine paraffin sections, sections taken, stained by hematoxylin and eosin and examined under light microscope, using 40× objective and 10× eyepiece. Apoptotic bodies were counted in each high-power field (HPF). Standard error of difference in apoptotic count in different tumor groups found and P value calculated, using Student's t test. An inverse correlation of the apoptotic count per HPF with the histological grade of the tumor was found. Grading of squamous cell carcinoma of esophagus, solely on the basis of apoptotic count can be used in the first place or to corroborate conventional histological grading done on the basis of morphology.
    Journal of laboratory physicians 03/2009; 1(1):11-4. DOI:10.4103/0974-2727.54801
  • [Show abstract] [Hide abstract]
    ABSTRACT: Benign and malignant tumors of the testes and paratesticular tissues present an interesting spectrum of diagnostic entities often encountered in routine surgical pathology practice. Germ cell tumors are the most common tumors of the testes and, despite a rising incidence, have excellent prognosis because of their radiosensitivity and/or effective chemotherapeutic agents. The proper classification of these tumors aids in the choice of appropriate treatment options. This article reviews benign and malignant neoplastic entities of the testes and paratesticular tissues and illustrates the classic pathologic characteristics. The differential diagnosis, along with ancillary studies, clinical significance, and presentation are discussed also.
    Surgical Pathology Clinics 03/2009; 2(1):61-159. DOI:10.1016/j.path.2008.08.007
Show more